A cohort study of acute pancreatitis in relation to exenatide use
The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
Aim: Reports of acute pancreatitis associated with exenatide treatment prompted this study to estimate the association between acute pancreatitis and exenatide use relative to other antihyperglycaemic drugs. Methods: This cohort study included patients without claims for prior pancreatic disease who initiated exenatide or other antihyperglycaemic drugs between June 2005 and December 2007. Acute pancreatitis was identified with diagnosis codes and confirmed through review of blinded medical records. Poisson regression models provided estimates of rate ratios (RRs) and 95% confidence intervals (CIs) comparing the rate of acute pancreatitis during periods of current (days supplied + 31 days), recent (current definition + 31 days) and past use (≥32 days beyond current definition) of exenatide relative to other antihyperglycaemic drugs, adjusted for propensity scores. A prespecified nested case–control analysis provided RR estimates adjusted for patient characteristics abstracted from medical records. Results: Initiators of exenatide (N = 25719) had more baseline claims for obesity and concomitant diabetes drugs than comparators (N = 234536). There were 40 confirmed cases of acute pancreatitis in the exenatide cohort and 254 among other antihyperglycaemic drug initiators. Compared to other antihyperglycaemic drugs, the propensity score‐adjusted RR for exenatide was 0.5 (95% CI 0.2–0.9) for current use, 1.1 (95% CI 0.4–3.2) for recent use and 2.8 (95% CI 1.6–4.7) for past use. The case–control analysis resulted in a RR of 0.2 for current use (95% CI 0.0–1.4) and 0.1 for recent use (95% CI 0.0–1.3), but an attenuated RR in the past use association (RR 1.1; 95% CI 0.1–11.0). Conclusions: Exenatide use was not associated with an increased risk of acute pancreatitis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Schafer, J. L. (1999) · Statistical Methods in Medical Research · doi:10.1177/096228029900800102 · Cited by 3,949
Evaluating medication effects outside of clinical trials: new-user designs
Ray, W. A. (2003) · American Journal of Epidemiology · doi:10.1093/aje/kwg231 · Cited by 1,646 · cited 1×
“We formed cohorts of exenatide and other antihyperglycaemic drug initiators [19], identified by their first pharmacy claim for the study drug preceded by 9 months of continuous health plan enrollment without a claim for the same drug (figure 1).”
BackgroundSchneeweiss, S., Rassen, J. A., Glynn, R. J., Avorn, J., Mogun, H., & Brookhart, M. A. (2009) · Epidemiology · doi:10.1097/ede.0b013e3181a663cc · Cited by 1,128 · cited 1×
“The aim of this empirical variable selection was to identify factors which differed between the exposure groups that may be unrecognized correlates of exenatide use that if risk factors (or proxies for unmeasured risk factors) for acute pancreatitis would confound the association [21].”
BackgroundBiochemical and histological effects of exendin-4 (exenatide) on the rat pancreas
Nachnani, J. S., Bulchandani, D. G., Nookala, A., Herndon, B., Molteni, A., Pandya, P., Taylor, R., Quinn, T., Weide, L., & Alba, L. M. (2010) · Diabetologia · doi:10.1007/s00125-009-1515-4 · Cited by 189
Exenatide (Exendin-4)–Induced Pancreatitis
Denker, P. S., & Dimarco, P. E. (2006) · Diabetes Care · doi:10.2337/diacare.29.02.06.dc05-2043 · Cited by 140 · cited 2×
“Postmarketing cases of pancreatitis were reported in patients on exenatide [3,4], prompting product label updates [2,5,6].”
BackgroundResult
Research works printed but not linked: 25
- 10.1016/j.clinthera.2007.11.006 · DOI · Paper page
- 10.1056/NEJMc0707137 · DOI · Paper page
- 10.1007/s00125-009-1556-8 · DOI · Paper page
- 10.2337/dc09-1902 · DOI · Paper page
- 10.1007/s00125-009-1591-5 · DOI · Paper page
- 10.2337/db09-0058 · DOI · Paper page
- 10.2337/db09-0626 · DOI · Paper page
- 10.1152/ajpendo.00479.2010 · DOI · Paper page
- 10.2337/dc08-1755 · DOI · Paper page
- 10.1097/MLR.0b013e31805371bf · DOI
- 10.1093/oxfordjournals.aje.a115198 · DOI · Paper page
- 10.1002/pds.611 · DOI
- Carroll JK, 2007, Acute pancreatitis: diagnosis, prognosis, and treatment., Am Fam Physician, 75, 1513
- 10.1002/9780470316696 · DOI · Paper page
- 10.1185/03007990902820519 · DOI · Paper page
- 10.1016/S0149-2918(98)80007-6 · DOI · Paper page
- Sachs RM, 1986, An evaluation of spontaneous adverse drug reaction monitoring systems., Am J Med, 81, 49
- Weber JCP., 1984, In: Rainsford KD, Velo GP, eds. Advances in Inflammation Research, Vol. 6.
- 10.1016/S0140-6736(08)60107-5 · DOI · Paper page
- Rodgers A, 1995, Systematic underestimation of treatment effects as a result of diagnostic test inaccuracy: implications for the interpretation and design of thromboprophylaxis trials., Thromb Haemost, 73, 167, 10.1055/s-0038-1653746 · DOI · Paper page
- 10.2337/diacare.25.2.298 · DOI · Paper page
- 10.1186/1471-230X-9-18 · DOI
- 10.1001/archinte.166.21.2369 · DOI · Paper page
- 10.1016/S0895-4356(00)00259-6 · DOI
- Tennerand Steinberg. Drug‐Induced Pancreatitis. In: Beger HG Warshaw AL Sarr MG et al. eds. The Pancreas Vol. 2. Oxford UK: Wiley‐Blackwell 1998;331–342.
Cited by
Handelsman, Y., Bloomgarden, Z. T., Grunberger, G., Umpierrez, G., Zimmerman, R. S., Bailey, T. S., Blonde, L., Bray, G. A., Cohen, A. J., Dagogo-Jack, S., et al. (2015) · Endocrine Practice · doi:10.4158/ep15672.gl · Cited by 629
Handelsman, Y., Bloomgarden, Z. T., Grunberger, G., Umpierrez, G., Zimmerman, R. S., Bailey, T. S., Blonde, L., Bray, G. A., Cohen, A. J., Dagogo-Jack, S., et al. (2015) · Endocrine Practice · doi:10.4158/ep15672.glsuppl · Cited by 559
Filippatos, T. D., Panagiotopoulou, T. V., & Elisaf, M. S. (2014) · The Review of Diabetic Studies · Cited by 560
Singh, S., Chang, H.-Y., Richards, T. M., Weiner, J. P., Clark, J. M., & Segal, J. B. (2013) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2013.2720 · Cited by 467
“Another cohort study reported no significantly increased risk of acute pancreatitis with exposure to exenatide relative to other antihyperglycemics after propensity score adjustment but had limited statistical power and a limited exposure window.(13) In that study, the use of exenatide beyond 32 days was associated wi…”
A Critical Analysis of the Clinical Use of Incretin-Based Therapies
Butler, P. C., Elashoff, M., Elashoff, R., & Gale, E. A. M. (2013) · Diabetes Care · doi:10.2337/dc12-2713 · Cited by 296
“(2) examined the frequency of pancreatitis in a claims database comprising 25,700 patients on exenatide (past or present users) as compared with 234,500 patients on other antihyperglycemic therapies.”
Metadata
- Authors
- Dore, D. D., Bloomgren, G. L., Wenten, M., Hoffman, C., Clifford, C. R., Quinn, S. G., Braun, D. K., Noel, R. A., & Seeger, J. D.
- Venue
- Diabetes, Obesity and Metabolism
- Publisher
- Wiley
- Published
- 2011-04-20
- Volume
- 13
- Issue
- 6
- Pages
- 559-566
- ISSN
- 1462-8902 (ISSN-L)
- 1463-1326
- OpenAlex
- W2094195067
- Cited by
- 144
- References
- 5
- FWCI
- 30.13
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A cohort study of acute pancreatitis in relation to exenatide use. https://app.cochat.ai/papers/10.1111/j.1463-1326.2011.01376.x
- The paper
- Dore, D. D., Bloomgren, G. L., Wenten, M., Hoffman, C., Clifford, C. R., Quinn, S. G., Braun, D. K., Noel, R. A., & Seeger, J. D. (2011). A cohort study of acute pancreatitis in relation to exenatide use. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/j.1463-1326.2011.01376.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.